TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Trending·November 16, 2026

Summit Therapeutics Inc. (SMMT) falls 12% after FDA CRL

Summit Therapeutics Inc. (SMMT) falls sharply after the FDA issued a Complete Response Letter for ivonescimab, its lead oncology drug. The setback follows concerns over survival data from the HARMONi study, pressuring the stock and delaying the company’s U.S. approval timeline.

TrendingSMMT
By TickerSpark·November 16, 2026·5 min read
Summit Therapeutics Inc. (SMMT) falls 12% after FDA CRL
▌Key Takeaway
Summit Therapeutics Inc. (SMMT) fell 12% in extended-hours trading after the FDA issued a Complete Response Letter for ivonescimab, its lead oncology asset. The agency’s decision centered on insufficient evidence of a statistically significant overall survival benefit in the HARMONi study, pushing back the drug’s U.S. approval path and weakening the stock’s near-term investment case.

Summit Therapeutics Inc. (NASDAQ: SMMT) falls 12.01% in extended-hours trading, moving from the prior regular-session close of $14.15 to $12.45 at 7:34 a.m. ET on Nov. 16. The sharp decline follows a major FDA setback for ivonescimab, and regular-session trading will confirm whether the after-hours loss holds.

Key Takeaways

  • SMMT traded at $12.45 in extended-hours trading, down 12.01% from the previous regular-session close.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

The primary catalyst is a Nov. 15 FDA Complete Response Letter for ivonescimab, Summit's lead oncology asset.
  • The FDA cited insufficient evidence of a statistically significant overall survival benefit in the HARMONi study.
  • Summit's latest quarterly EPS beat estimates, but the company still lists EPS of -$1.06 and has a $11.29B market cap.
  • The investment case now depends more heavily on the FDA response, additional clinical evidence, and the timing of a possible U.S. approval.
  • Why Summit Therapeutics Inc. (SMMT) Is Falling After the FDA CRL

    The catalyst is specific and company-driven. On Nov. 15, Summit announced that the FDA issued a Complete Response Letter for its biologics license application covering ivonescimab with platinum-containing chemotherapy. The application targeted patients with locally advanced or metastatic non-small cell lung cancer after prior EGFR TKI therapy. followed a Nov. 14 PDUFA date, placing the decision directly inside the trading window investors had been tracking.

    A Complete Response Letter means the FDA did not approve the application in its current form. News coverage tied the decision to the HARMONi study's failure to show a statistically significant overall survival benefit. That distinction matters. The market is reacting to an efficacy concern tied to the main dataset, rather than a routine administrative delay.

    Ivonescimab represented Summit's most important near-term U.S. commercial opportunity. Therefore, the FDA action pushes back the potential revenue timeline and lowers the probability-adjusted value of the program. For a development-stage biotech, that is a direct hit to the central equity thesis.

    How SMMT Earnings and Valuation Frame the Biotech Selloff

    The latest earnings result does not explain the decline. Summit reported EPS of -$0.26 on Nov. 4 against an estimate of -$0.28, producing a 7.1% positive surprise. However, the company's earnings history shows just 2 beats across the last 8 quarters. The FDA decision, rather than the latest EPS result, is the material event behind this move.

    Summit's fundamentals still show a loss-making development business. The stock data lists EPS at -$1.06, while the company carries an $11.29B market capitalization. That valuation places heavy weight on future product approval and commercial execution. When the FDA challenges the lead filing, the market has little current earnings power to cushion the repricing.

    Price history adds perspective. SMMT's 52-week range runs from $12.07 to $29.23, and the extended-hours print of $12.45 sits close to the low end of that range. A Nov. 10 market report also noted that the shares had closed at $17.84 after roughly a sevenfold three-year run. That earlier momentum helps explain why a binary regulatory setback produced such a fast reversal.

    Ivonescimab Pipeline and Summit Therapeutics' Competitive Position

    Ivonescimab is a bispecific antibody designed to combine PD-1 blockade with an anti-angiogenesis mechanism. Summit is developing the drug for non-small cell lung cancer and colorectal cancer, and the company has also studied combinations with chemotherapy in Phase III programs.

    That pipeline gives Summit more than one clinical program, but the rejected NSCLC application carried the clearest near-term commercial importance. The FDA's survival concern weakens the competitive narrative until Summit addresses the evidence behind the HARMONi result. In oncology, a promising mechanism matters less when the pivotal survival data fail to satisfy regulators.

    The stock's previous analyst support also deserves careful treatment. Citizens reiterated a Market Outperform rating with a $40 target on Oct. 27, while the analyst consensus listed 15 Buy ratings, 8 Holds, and zero Sell ratings. Those opinions came before or around the regulatory event and do not provide a reliable floor after a CRL. A regulatory setback can make older targets stale in a single session, which is one of biotech's less charming traditions.

    What SMMT Investors Should Do After the After-Hours Drop

    Investors should first separate the FDA event from the earnings story. The Nov. 4 EPS beat offers limited protection because Summit remains loss-making and the regulatory decision affects the company's lead asset. A lower share price alone does not repair the clinical evidence issue.

    Second, position size matters. The $12.07 52-week low and the $14.15 prior close provide clear reference points for judging price action, but neither level confirms value. The stock can stabilize near those prices only if buyers accept the revised approval risk, not simply because the shares have fallen.

    Third, focus on the regulatory remedy. The relevant investment test is whether Summit can address the FDA's concerns with additional analyses, clinical evidence, or other requested information and establish a credible path for the ivonescimab application. Until that path becomes concrete, SMMT remains an event-driven biotech rather than a conventional earnings compounder.

    Finally, avoid treating old price targets as a valuation anchor. The $33.13 consensus target was built before the CRL and reflects a different probability of U.S. approval. A disciplined approach gives greater weight to the FDA decision and the company's response than to analyst targets published before the setback.

    Bottom Line for Summit Therapeutics Inc. Investors

    SMMT falls because the FDA rejected the current ivonescimab application after the HARMONi study failed to show a statistically significant overall survival benefit. The negative EPS profile and $11.29B market cap amplify the impact because investors valued Summit mainly on future approval and commercialization potential. The after-hours decline is a sharp reset of that expectation, and regular-session price action will show whether the market accepts the new risk level.

    Read the full SMMT research report
    ▌Common Questions

    Frequently asked questions

    +Why is SMMT stock down today?
    SMMT is down because the FDA issued a Complete Response Letter for ivonescimab, Summit’s lead drug candidate. The agency cited insufficient evidence of a statistically significant overall survival benefit, which hurt the stock’s approval outlook.
    +Should I buy SMMT stock now?
    Not on this news alone. The FDA setback materially raises approval risk, so investors should wait for clearer evidence that Summit can address the agency’s concerns before treating the drop as a buying opportunity.
    +What does the FDA Complete Response Letter mean for Summit Therapeutics?
    A Complete Response Letter means the FDA did not approve the application in its current form. Summit will need to provide more data or additional analysis before ivonescimab can move forward in the U.S. approval process.
    +Is the earnings report the reason SMMT fell?
    No, the earnings report is not the main driver of the decline. The stock is falling because of the FDA decision on ivonescimab, which is far more important to Summit’s valuation than its latest EPS result.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on SMMT?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the SMMT report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full SMMT research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the SMMT report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on SMMT

    More to read

    All articles
    Summit Therapeutics (SMMT): Ivonescimab Could Drive a Breakout
    SMMT

    Summit Therapeutics (SMMT): Ivonescimab Could Drive a Breakout

    Summit Therapeutics is a high-risk oncology biotech whose fate hinges on ivonescimab and upcoming FDA/regulatory decisions. Strong Phase III data support the story, but heavy cash burn, no revenue, and dilution risk keep the stock at Hold.

    Oct 11·19 min
    Summit Therapeutics Inc. (SMMT) rises on AstraZeneca deal
    SMMT

    Summit Therapeutics Inc. (SMMT) rises on AstraZeneca deal

    Summit Therapeutics Inc. (SMMT) rises after AstraZeneca’s $2 billion strategic investment sparked heavy trading and renewed confidence in the company’s lead cancer drug, ivonescimab. The move highlights investor enthusiasm for the partnership, but the stock still carries biotech execution, clinical, and dilution risk.

    Sep 30·5 min
    Summit Therapeutics Inc. (SMMT) jumps on AstraZeneca $2B deal
    SMMT

    Summit Therapeutics Inc. (SMMT) jumps on AstraZeneca $2B deal

    Summit Therapeutics Inc. (SMMT) jumps after AstraZeneca announced a $2 billion strategic investment and trial collaboration tied to ivonescimab. The deal boosts funding, validates the pipeline, and lifted shares in extended-hours trading, though clinical, dilution, and valuation risks remain for investors.

    Sep 29·5 min